Pinned straw:
In prep for tonight's session on Nova Eye, I used Google Gemini's NotebookLM to create this 7 minute video summary.
This only uses material posted on Strawman and does not reference any external content, such as company reports, announcements or broker reports.
Of course, like most AI generated stuff, it's not perfect. But it does a reasonable job of capturing the general vibe of what members have said.
Let us know what you think.
Click the image to watch:
Love the AI summary @Strawman.This is exactly what I’ve been looking for. I’ve found it difficult to navigate the volume of content on Strawman just to get a quick snapshot of a company’s core business and current status.
These summaries would be my ideal first stop; if a company piques my interest, I can then drill down into individual comments for more detail. While I value the diverse perspectives, the sheer amount of content can be overwhelming when you just want the 'low down.' I’m not complaining—I just firmly believe that constructive feedback helps a product become even more effective.
Of course this would need to be highlighted somehow (preferably not posted amongst a large amount of content for that company) as a heading etc at the top of a companies profile with a date saying when it was last created, showing its relevance to the time being viewed. Nice Job
@Strawman what a great video.
I think the one area we haven't looked at enough is the comparison with OMNI. Sight Sciences have a great video here and, I think when you watch it, you can see that the summary table in the AI video is a simplification and possibly a little misleading.
To be honest, I don't really understand what is limiting the growth of OMNI. It is clear that the net growth in canaloplasty is going to iTrack, but I can't see sufficient differentiation between OMNI and iTrack as products with respect to canaloplasty to explain the difference in sales growth.
Is is that Sight Sciences are locked in with a much higher sales forces that their pricing is higher? What initiatives might they take to fight back? OR is it that the US profession is more rusted on to Stents, SLT and droplets? After all, the clinical evidence isn't strong.
So while on the one hand the new variant of iTrack is getting strong revenue growth AND the sales force is underpowered, how strong is the market opportunity really? Because I don't really understand why OMNI is flat, I don't understand the answer to that question.
I hope this is something we can explore in today's meeting.
OK. That's it from me. Head down for valuation!